- Autoimmune Disorders in Women Possibly Triggered by Seafood
- FDA Approves Noninvasive Colorrectal Cancer Test
- FDA Approves Limited Use of Drug for Ebola
- FDA Approves Edwards Lifesciences Corporation’s Sapien XT
- Lymphoseek Injections Approved by FDA for Prolonged Extended Use
- Orexigen Therapeutics’ Contrave Awaits FDA’s Nod
- FDA Expressed Concern on E-Cigarette Smoking after Increase in Complaint Rate
- E-Cigarette Marketing to Be Regulated by FDA Appealed As They Pose Serious Threat to the Youth
- FDA Goes Tough on Honey with Added Sweeteners
- Is Your Honey Adulterated?
Promising News for Psoriatic Arthritis Patients
- Updated: June 12, 2014
Psoriatic arthritis is a disease which can not only affect the quality of life of the patient but also cause disability. It attacks nearly 30% of people who already have psoriasis, which causes reddish and sometimes white itchy, scaly patches on the skin. When the immune system becomes too weak, joints may also get affected and there could be severe inflammation and even joint damage in some cases.
A new drug known as Brodalumab has proven to be effective against psoriatic arthritis, according to a study. It was found that patients responded well to the drug and not only experienced improved skin condition but also reduced swelling of fingers and toes.
The lead researcher, a rheumatologist from the Swedish Medical Center, Seattle, Dr., Philip Mease, also stated that that the mechanism of action of this drug is quite different from that of drugs which are conventionally used for the condition. According to him, psoriatic arthritis is different from other forms of arthritis as it involves a genetic component also.
Regular medicines came with adverse side effects and after a point, patients lost response to them. With the aim of developing a drug that helped bring patients back to their normal condition, this study was carried out with 168 psoriatic arthritis patients getting randomly assigned with a placebo or varying doses of Brodalumab. After 12 weeks, it was observed that patients who were given Brodalumab exhibited better response to treatment compared to those who were on placebo.
The study was funded by Amgen and showed that there was considerable improvement in clinical symptoms of patients who took Brodalumab. Brodalumab works by binding to interleukin-17 receptors and blocked the binding of interleukin-17 ligands to the receptor to stop inflammatory signaling. It was also found that responses continued to improve with time.